NEW YORK (GenomeWeb) – ExcitePCR has been developing a real-time, point-of-care technology called FireflyDx that diagnoses diseases using a wide variety of sample types and requires as little as 10 minutes for sample preparation time.
The company is currently developing two devices based on the technology: the FireflyDx-Portable, which fits in a backpack and is planned for commercial release in summer 2018; and the FireflyDX-Handheld, which is planned for a commercial launch in 2019, ExcitePCR CMO David Politis said. He added that the technology will detect pathogens in situations where real-time results can prevent infectious diseases from rapidly spreading.
Tracing its origin back to 2004, ExcitePCR originally began as Microfluidic Systems, one of seven companies awarded contracts by the US Department of Homeland Security (DHS) to develop a solution to automatically detect airborne pathogens. The firm received over $35 million in DHS funding before Positive ID acquired Microfluidic Systems in 2011 with the intent of developing portable real-time biohazard detection systems. Then, earlier this year PositiveID formed ExcitePCR as a subsidiary to further develop and commercialize the Firefly technology.
Politis explained that compared to some other POC devices, which can weigh 50 to 70 lbs and require the use of